Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants

(2015) J R Passweg et al.   BONE MARROW TRANSPLANTATION

Chronic myeloid leukaemia

(2015) Jane F Apperley   LANCET

The impact of health care settings on survival time of patients with chronic myeloid leukemia

(2014) M. Lauseker et al.   BLOOD

Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

(2014) X-D Mo et al.   BONE MARROW TRANSPLANTATION

Chronic Myeloid Leukemia–Transplantation in the Tyrosine Kinase Era

(2014) Andrew J. Innes et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia

(2014) Markus Pfirrmann et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry

(2014) Loren Gragert et al.   NEW ENGLAND JOURNAL OF MEDICINE

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study

(2013) A. Gratwohl et al.   HAEMATOLOGICA

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

(2013) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

(2012) Anthony Oyekunle et al.   ANNALS OF HEMATOLOGY

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

(2012) E. Warlick et al.   BLOOD

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

(2011) S. Soverini et al.   BLOOD

Introduction of a Quality Management System and Outcome After Hematopoietic Stem-Cell Transplantation

(2011) Alois Gratwohl et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

(2010) T. P. Hughes et al.   BLOOD

Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation

(2010) Ted A. Gooley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

(2009) S. Saussele et al.   BLOOD